Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2006-09-12
2006-09-12
Parkin, Jeffrey S. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C435S005000, C530S350000
Reexamination Certificate
active
07105169
ABSTRACT:
The present invention provides, among other things, methods of removing virus from a sample, a composition comprising a solid support matrix to which is attached a cyanovirin, a conjugate comprising a cyanovirin coupled to at least one effector component, a composition comprising such a conjugate, methods of inhibiting prophylactically or therapeutically a viral infection of a host, and a matrix-anchored anti-cyanovirin antibody.
REFERENCES:
patent: 3470069 (1969-09-01), Warren et al.
patent: 4935465 (1990-06-01), Garman
patent: 5266478 (1993-11-01), Chang et al.
patent: 5445960 (1995-08-01), Masuho et al.
patent: 5558865 (1996-09-01), Ohno
patent: 5618922 (1997-04-01), Ohno et al.
patent: 5821081 (1998-10-01), Boyd et al.
patent: 6420336 (2002-07-01), Boyd
patent: 2124545 (1995-11-01), None
patent: 3828842 (1989-10-01), None
patent: 459779 (1991-12-01), None
patent: 465979 (1992-01-01), None
patent: 503916 (1992-09-01), None
patent: 516135 (1993-05-01), None
patent: 581353 (1993-05-01), None
patent: 6141885 (1994-05-01), None
patent: 95939 (1991-09-01), None
patent: WO 90/12868 (1990-11-01), None
patent: WO 91/09625 (1991-07-01), None
patent: WO 91/11198 (1991-08-01), None
patent: WO 91/17764 (1991-11-01), None
patent: WO 92/07878 (1992-05-01), None
patent: WO 92/08491 (1992-05-01), None
patent: WO 92/08983 (1992-05-01), None
patent: WO 93/15885 (1992-09-01), None
patent: WO 93/04090 (1993-03-01), None
patent: WO 93/06216 (1993-04-01), None
patent: WO 93/12232 (1993-06-01), None
patent: WO 94/04574 (1994-03-01), None
patent: WO 94/07922 (1994-04-01), None
patent: WO 94/19017 (1994-09-01), None
patent: WO 94/28933 (1994-12-01), None
patent: WO 95/06119 (1995-03-01), None
patent: WO 95/24215 (1995-09-01), None
patent: WO 96/02273 (1996-02-01), None
patent: WO 96/34107 (1996-10-01), None
patent: WO 96/40294 (1996-12-01), None
patent: WO 99/19500 (1999-04-01), None
Abuchowski et al., Alteration of Immunological Properties of Bovine Serum Albumin by Covalent Attachment of Polyethylene Glycol,Journal of Biological Chemistry, 252(11), 3578-3581 (1977).
Abuchowski et al., “Soluble Polymer-Enzyme Adducts,”in Enzymes as Drugs, Holcenberg et al., eds., John Wiley: New York, 1981, pp. 367-383.
Agnew et al., “The Effect of Treatment Regimens for Vaginitis and Cervicitis on Vaginal Colonization by Lactobacilli,”Sexually Transmitted Diseases, 22 (5), 269-273 (1995).
Andreu et al., “Hemagglutination Adherence, and Surface Properties of Vaginal Lactobacillus Species,”J. Infect Diseases, 171, 1237-1243 (1995).
Aullo et al., “A Recombinant Diphtheria Toxin Related Human CD4 Fusion Protein Specifically Kills HIV Infected Cells Which Express gp120 But Selects Fusion Toxin Resistant Cells Which Carry HIV,”EMBO Journal, 11(2), 575-583 (1992).
Balter, “UN Readies New Global AIDS Plan,”Science, 266, 1312-1313 (1994).
Banga et al., “Systemic Delivery of Therapeutic Peptides and Proteins,”International Journal of Pharmaceutics, 48, 15-50 (1988).
Barry, “The Transdermal Route for the Delivery of Peptides and Proteins,”in Delivery Systems for Peptide Drugs, Davis et al. eds., Plenum Press: New York, 1986, pp. 265-275.
Berzofsky, “Approaches and Issues in the Development of Vaccines Against HIV,”Journal of Acquired Immune Deficiency Syndromes, 4, 451-459 (1991).
Bird, “The Use of Spermicide Containing Nonoxynol-9 in the Prevention of HIV Infection,”AIDS, 5(7), 791-796 (1991).
Bourinbaiar et al., “Anti-HIV Effect of Gramicidin In Vitro: Potential for Spermicide Use,”Life Sciences, 54(1), 5-9 (1994).
Bourinbaiar et al., “Comparative In Vitro Study of Contraceptive Agents with Anti-HIV Activity: Gramicidin, Nonoxynol-9, and Gossypol,”Contraception, 49, 131-137 (1994).
Bowie et al., “Deciphering the Message in the Protein Sequences: Tolerance to Amino Acid Substitutions,”Science, 247, 1306-1310 (1990).
Boyd et al., “Anti-HIV Michellamines formAncistrocladus korupensis,” Journal of Medicinal Chemistry, 37(12), 1740-1745 (1994).
Boyd et al., “Discovery of Cyanovirin-N, a Novel Human Immunodeficiency Virus-Inactivating Protein That Binds Viral Surface Envelope Glycoprotein gp120: Potential Applications to Microbicide Development”,Antimicrobial Agents and Chemotherapy, 41(7), 1521-1530 (1997).
Boyd, “Strategies for the Identification of New Agents for the Treatment of AIDS: A National Program to Facilitate the Discovery and Preclinical Development of New Drug Candidates for Clinical Evaluation,”AIDS Etiology, Diagnosis, Treatment, and Prevention, Second Edition, DeVita et al., eds., J.B. Lippincott Company, 1988, pp. 305-317.
Bruce et al., “Intravaginal instillation of Lactobacilli for Prevention of Recurrent Urinary Tract Infections,”Can J. Microbiol, 34, 339-343 (1988).
Buckheit et al., “Biological and Biochemical Anti-HIV Activity of the Benzothiadiazine class Nonnucleoside Reverse Transcriptase Inhibitors,”Antiviral Research, 25, 43-56 (1994).
Capon et al., “Designing CD4 Immunoadhesins for AIDS Therapy,”Nature, 337, 525-531 (1989).
Capon et al., “The CD4-gp120 Interaction and AIDS Pathogenesis,”Annu. Rev. Immunol., 9, 649-678 (1991).
Carone et al., “Renal Tubular Processing of Small Peptide Hormones,”The Journal of Laboratory and Clinical Medicine, 100(1), 1-14 (1982).
Carpenter et al.,JAMA, 280(1), 78-86 (1998).
Carter et al., “Structure of Majusculamide C, a Cyclic Depsipeptide fromLyngbya majuscula,” J. Org. Chem., 49, 236-241 (1984).
Chan et al., “HIV Entry and its Inhibition,”Cell, 93, 681-684 (1998).
Chaudhary et al., “CD4-PE4O—A Chimeric Toxin Active Against Human Immunodeficiency Virus (HIV)-Infected Cells,”The Human Retroviruses, pp. 379-387 (1991).
Chaudhary et al., “Selective Killing of HIV-Infected Cells by Recombinant Human CD4-Pseudomonas Exotoxin Hybrid Protein,” Nature, 335, 369-372 (1988).
Coffin, John M., “HIV Population Dynamics In Vivo: Implications for Genetic Variation, Pathogenesis, and Therapy,”Science, 267, 483-489 (1995).
Cohen et al.,JAMA 280(1), 87-88 (1998).
Cohen, “High Turnover of HIV in Blood Revealed by New Studies,”Science, 267, (1995).
Coll et al., “The Application of Vacuum Liquid Chromatograph to the Separation of Terpene Mixtures,”Journal of Natural Products, 49(5), 934-936 (1986).
Davey et al., “Use of Recombinant Soluble CD4PseudomonasExotoxin, a Novel Immunotoxin, for Treatment of Persons Infected with Human Immunodeficiency Virus,”Journal of Infectious Diseases, 170, 1180-1188 (1994).
Davis, “Delivery Systems for Bipharmaceuticals,”J. Pharmacol., 44(Suppl. 1), 186-190 (1992).
Davis, et al., “Reduction of Immunogenicity and Extension of Circulating Half-Life of Peptides and Proteins,”Peptide and Protein and Drug Delivery, Marcel Dekker, Inc., New York: 1991 (831-864).
De Clercq., “Antiviral Agents: Characteristic Activity Spectrum Depending on the Molecular Target with Which They Interact,”Advances In Virus Research, 42, 1-55 (1993).
De Clercq, “Basic Approaches to Anti-Retroviral Treatment,”Journal of Acquired Immune Deficiency Syndromes, 4(3), 207-218 (1991).
Deasy et al., inMicroencapsulation and Related Processes, Swarbrick J., ed., Marcel Dekker, Inc.: New York, 1984, pp. 1-60.
Denton et al., “Clinical Outcome of Colorectal Cancer Patients Treated with Human Monoclonal Anti-Idiotypic Antibody,”Int. J. Cancer, 57, 10-14 (1994).
Elmer et al., “Biotherapeutic Agents,”JAMA, 275(11), 870-876 (1996).
Emtage, “Biotechnology and Protein Production,” inDelivery Systems for Peptide Drugs, Davis et al., eds., Plenum Press: New York, 1986, pp. 23-33.
Eppstein et al., “Alternative Delivery Systems for Peptides and Proteins as Drugs,”CRC Critical Reviews in Therapeutic Drug
Leydig , Voit & Mayer, Ltd.
Parkin Jeffrey S.
The United States of America as represented by the Department of
LandOfFree
Cyanovirin conjugates and matrix-anchored cyanovirin and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyanovirin conjugates and matrix-anchored cyanovirin and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyanovirin conjugates and matrix-anchored cyanovirin and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3575357